Feng Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Feng Gu has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Li Fu
Department of Rehabilitation School of Medical Technology, Tianjin Medical University Tianjin China
6 shared publications - Yongjie Ma
Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
6 shared publications Xiaoli Liu
Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
5 shared publicationsHuikun Zhang
Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
4 shared publications- Li Fu
Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 shared publications Fengxia Qin
Department of Breast Cancer Pathology and Research Laboratory, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), National Clinical Research Center for Cancer, Tianjin, China
3 shared publications
Latest Publications
- Open Access
- 1 January 2023
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 19 (3) , 831
A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation: Erratum
[This corrects the article DOI: 10.7150/ijbs.36429.].
- 1 January 2023
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 19 (3) , 831
Open AccessA Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation: Erratum
[This corrects the article DOI: 10.7150/ijbs.36429.].
- Open Access
- 28 September 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (9) , 1-15
The alternative splicing of intersectin 1 regulated by PTBP1 promotes human glioma progression
Intersectin 1 (ITSN1) contains two isoforms: ITSN1-S and ITSN1-L, which are highly regulated by alternative splicing. Our previous results showed that the two isoforms of ITSN1 displayed opposite functions: ITSN1-S promoted glioma development, while ITSN1-L exerted an inhibitory role in glioma progression. In this study, our transcriptome analysis using a large glioma cohort indicated that the ratio of ITSN1-S/ITSN1-L was positively correlated with glioma grading and poor prognosis. We identified the RNA-binding protein polypyrimidine tract-binding protein 1 (PTBP1) as an ITSN1 pre-mRNA interaction protein through RNA pull-down assay and RNA immunoprecipitation assay. Knockdown of PTBP1 decreased the ratio of ITSN1-S/ITSN1-L. Minigene reporter assay and mutation analyses further confirmed PTBP1 targeted polypyrimidine sequences on ITSN1 exon 30 (TTGCACTTCAGTATTTT) and promoted the inclusion of ITSN1 exon 30. Subsequently, silencing PTBP1 inhibited glioma cell proliferation, migration, and invasion by down-regulating the ratio of ITSN1-S/ITSN1-L. Taken together, our study provides a novel mechanism that PTBP1 modulates the alternative splicing of ITSN1 and promotes glioma proliferation and motility by up-regulating the ratio of ITSN1-S/ITSN1-L, thereby highlighting that PTBP1 may be an attractive therapeutic target for gliomas.
- 28 September 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (9) , 1-15
Open AccessThe alternative splicing of intersectin 1 regulated by PTBP1 promotes human glioma progression
Intersectin 1 (ITSN1) contains two isoforms: ITSN1-S and ITSN1-L, which are highly regulated by alternative splicing. Our previous results showed that the two isoforms of ITSN1 displayed opposite functions: ITSN1-S promoted glioma development, while ITSN1-L exerted an inhibitory role in glioma progression. In this study, our transcriptome analysis using a large glioma cohort indicated that the ratio of ITSN1-S/ITSN1-L was positively correlated with glioma grading and poor prognosis. We identified the RNA-binding protein polypyrimidine tract-binding protein 1 (PTBP1) as an ITSN1 pre-mRNA interaction protein through RNA pull-down assay and RNA immunoprecipitation assay. Knockdown of PTBP1 decreased the ratio of ITSN1-S/ITSN1-L. Minigene reporter assay and mutation analyses further confirmed PTBP1 targeted polypyrimidine sequences on ITSN1 exon 30 (TTGCACTTCAGTATTTT) and promoted the inclusion of ITSN1 exon 30. Subsequently, silencing PTBP1 inhibited glioma cell proliferation, migration, and invasion by down-regulating the ratio of ITSN1-S/ITSN1-L. Taken together, our study provides a novel mechanism that PTBP1 modulates the alternative splicing of ITSN1 and promotes glioma proliferation and motility by up-regulating the ratio of ITSN1-S/ITSN1-L, thereby highlighting that PTBP1 may be an attractive therapeutic target for gliomas.
- 25 April 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 234, 153915
Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer
- 25 April 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 234, 153915
Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer
- Open Access
- 10 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast
Invasive micropapillary carcinoma (IMPC) has very high rates of lymphovascular invasion and lymph node metastasis and has been reported in several organs. However, the genomic mechanisms underlying its metastasis are unclear. Here, we perform whole-genome sequencing of tumor cell clusters from primary IMPC and paired axillary lymph node metastases. Cell clusters in multiple lymph node foci arise from a single subclone of the primary tumor. We find evidence that the monoclonal metastatic ancestor in primary IMPC shares high frequency copy-number loss of PRDM16 and IGSF9 and the copy number gain of ALDH2. Immunohistochemistry analysis further shows that low expression of IGSF9 and PRDM16 and high expression of ALDH2 are associated with lymph node metastasis and poor survival of patients with IMPC. We expect these genomic and evolutionary profiles to contribute to the accurate diagnosis of IMPC.
- 10 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessGenomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast
Invasive micropapillary carcinoma (IMPC) has very high rates of lymphovascular invasion and lymph node metastasis and has been reported in several organs. However, the genomic mechanisms underlying its metastasis are unclear. Here, we perform whole-genome sequencing of tumor cell clusters from primary IMPC and paired axillary lymph node metastases. Cell clusters in multiple lymph node foci arise from a single subclone of the primary tumor. We find evidence that the monoclonal metastatic ancestor in primary IMPC shares high frequency copy-number loss of PRDM16 and IGSF9 and the copy number gain of ALDH2. Immunohistochemistry analysis further shows that low expression of IGSF9 and PRDM16 and high expression of ALDH2 are associated with lymph node metastasis and poor survival of patients with IMPC. We expect these genomic and evolutionary profiles to contribute to the accurate diagnosis of IMPC.
- Open Access
- 20 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (12) , 1-11
Spatial transcriptomics reveals gene expression characteristics in invasive micropapillary carcinoma of the breast
Invasive micropapillary carcinoma (IMPC) is a special histological subtype of breast cancer, featured with extremely high rates of lymphovascular invasion and lymph node metastasis. Based on a previous series of studies, our team proposed the hypothesis of “clustered metastasis of IMPC tumor cells”. However, the transcriptomics characteristics underlying its metastasis are unknown, especially in spatial transcriptomics (ST). In this paper, we perform ST sequencing on four freshly frozen IMPC samples. We draw the transcriptomic maps of IMPC for the first time and reveal its extensive heterogeneity, associated with metabolic reprogramming. We also find that IMPC subpopulations with abnormal metabolism are arranged in different spatial areas, and higher levels of lipid metabolism are observed in all IMPC hierarchical clusters. Moreover, we find that the stromal regions show varieties of gene expression programs, and this difference depends on their distance from IMPC regions. Furthermore, a total of seven IMPC hierarchical clusters of four samples share a common higher expression level of the SREBF1 gene. Immunohistochemistry results further show that high SREBF1 protein expression is associated with lymph node metastasis and poor survival in IMPC patients. Together, these findings provide a valuable resource for exploring the inter- and intra-tumoral heterogeneity of IMPC and identify a new marker, SREBF1, which may facilitate accurate diagnosis and treatment of this disease.
- 20 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (12) , 1-11
Open AccessSpatial transcriptomics reveals gene expression characteristics in invasive micropapillary carcinoma of the breast
Invasive micropapillary carcinoma (IMPC) is a special histological subtype of breast cancer, featured with extremely high rates of lymphovascular invasion and lymph node metastasis. Based on a previous series of studies, our team proposed the hypothesis of “clustered metastasis of IMPC tumor cells”. However, the transcriptomics characteristics underlying its metastasis are unknown, especially in spatial transcriptomics (ST). In this paper, we perform ST sequencing on four freshly frozen IMPC samples. We draw the transcriptomic maps of IMPC for the first time and reveal its extensive heterogeneity, associated with metabolic reprogramming. We also find that IMPC subpopulations with abnormal metabolism are arranged in different spatial areas, and higher levels of lipid metabolism are observed in all IMPC hierarchical clusters. Moreover, we find that the stromal regions show varieties of gene expression programs, and this difference depends on their distance from IMPC regions. Furthermore, a total of seven IMPC hierarchical clusters of four samples share a common higher expression level of the SREBF1 gene. Immunohistochemistry results further show that high SREBF1 protein expression is associated with lymph node metastasis and poor survival in IMPC patients. Together, these findings provide a valuable resource for exploring the inter- and intra-tumoral heterogeneity of IMPC and identify a new marker, SREBF1, which may facilitate accurate diagnosis and treatment of this disease.
- 24 April 2021
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 27 (6) , 461-464
Treatment of End-Stage Coronary Artery Disease with the Mode of Combination of Disease and Syndrome: A Case Report
Conclusion Although cardiovascular mortality in end-stage CAD patient has declined due to improved secondary prevention, but new therapeutic strategies remains required. Transmyocardial laser revascularization, cardiac shock wave therapy, gene therapeutics and heart transplantation have now been accepted treatments for end-stage CAD, but remains lack of adequate clinical evidence. This case report showed that integrative medicine can awaken hibernation myocardium and reduction in symptoms of angina. Besides, psychology, rehabilitation, medical treatment and invasive interventions participate in the treatment of diseases together, in order to choose reasonable therapeutic regimen for the patients with more complex disease stage guided by the scientific and rational principle.
- 24 April 2021
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 27 (6) , 461-464
Treatment of End-Stage Coronary Artery Disease with the Mode of Combination of Disease and Syndrome: A Case Report
Conclusion Although cardiovascular mortality in end-stage CAD patient has declined due to improved secondary prevention, but new therapeutic strategies remains required. Transmyocardial laser revascularization, cardiac shock wave therapy, gene therapeutics and heart transplantation have now been accepted treatments for end-stage CAD, but remains lack of adequate clinical evidence. This case report showed that integrative medicine can awaken hibernation myocardium and reduction in symptoms of angina. Besides, psychology, rehabilitation, medical treatment and invasive interventions participate in the treatment of diseases together, in order to choose reasonable therapeutic regimen for the patients with more complex disease stage guided by the scientific and rational principle.
- Open Access
- 15 January 2020
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 52 (1) , 218-245
Anterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response
Anterior gradient 3 (AGR3) belongs to human anterior gradient (AGR) family. The function of AGR3 on cancer remains unknown. This research aimed to investigate if AGR3 had prognostic values in invasive ductal carcinoma (IDC) of breast cancer and could promote tumor progression. AGR3 expression was detected in breast benign lesions, ductal carcinoma in situ and IDC by immunohistochemistry analysis. AGR3's correlations with clinicopathological features and prognosis of IDC patients were analyzed. By cell function experiments, collagen gel droplet-embedded culture drug sensitivity test and cytotoxic analysis, AGR3's impacts on proliferation, invasion ability, and chemotherapeutic drug sensitivity of breast cancer cells were also detected. AGR3 was up-regulated in luminal subtype of histological grade I-II of IDC patients and positively correlated with high risks of recurrence and distant metastasis. AGR3 high expression could lead to bone or liver metastasis and predict poor prognosis of luminal B. In cell lines, AGR3 could promote proliferation and invasion ability of breast cancer cells which were consistent with clinical analysis. Besides, AGR3 could indicate poor prognosis of breast cancer patients treated with taxane but a favorable prognosis with 5-fluoropyrimidines. And breast cancer cells with AGR3 high expression were resistant to taxane but sensitive to 5-fluoropyrimidines. AGR3 might be a potential prognostic indicator in luminal B subtype of IDC patients of histological grade I-II. And patients with AGR3 high expression should be treated with chemotherapy regimens consisting of 5-fluoropyrimidines but no taxane.
- 15 January 2020
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 52 (1) , 218-245
Open AccessAnterior Gradient 3 Promotes Breast Cancer Development and Chemotherapy Response
Anterior gradient 3 (AGR3) belongs to human anterior gradient (AGR) family. The function of AGR3 on cancer remains unknown. This research aimed to investigate if AGR3 had prognostic values in invasive ductal carcinoma (IDC) of breast cancer and could promote tumor progression. AGR3 expression was detected in breast benign lesions, ductal carcinoma in situ and IDC by immunohistochemistry analysis. AGR3's correlations with clinicopathological features and prognosis of IDC patients were analyzed. By cell function experiments, collagen gel droplet-embedded culture drug sensitivity test and cytotoxic analysis, AGR3's impacts on proliferation, invasion ability, and chemotherapeutic drug sensitivity of breast cancer cells were also detected. AGR3 was up-regulated in luminal subtype of histological grade I-II of IDC patients and positively correlated with high risks of recurrence and distant metastasis. AGR3 high expression could lead to bone or liver metastasis and predict poor prognosis of luminal B. In cell lines, AGR3 could promote proliferation and invasion ability of breast cancer cells which were consistent with clinical analysis. Besides, AGR3 could indicate poor prognosis of breast cancer patients treated with taxane but a favorable prognosis with 5-fluoropyrimidines. And breast cancer cells with AGR3 high expression were resistant to taxane but sensitive to 5-fluoropyrimidines. AGR3 might be a potential prognostic indicator in luminal B subtype of IDC patients of histological grade I-II. And patients with AGR3 high expression should be treated with chemotherapy regimens consisting of 5-fluoropyrimidines but no taxane.
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (1) , 162-171
A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation
Great quantity of intergenic noncoding RNAs (lncRNAs) have been identified in the mammalian genome and involved in various biological processes, especially in the development and metastasis of cancer. In this study, we identified one lncRNA, lncRNA NONHSAT028712 (Lnc712), was highly expressed in breast cancer cell lines and tissues based on microarray screening. Knockdown of Lnc712 largely inhibited breast cancer cell proliferation. Mechanistically, Lnc712 bound specifically to heat-shock protein 90 (HSP90). Interaction between Lnc712 and HSP90 is required for HSP90 binding to cell division cycle 37 (Cdc37). The Lnc712/HSP90/Cdc37 complex regulated cyclin-dependent kinase 2 (CDK2) activation and then triggered breast cancer cell proliferation. In summary, our results identified a new lncRNA regulate breast cancer proliferation though interaction with HSP90.
- 1 January 2020
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (1) , 162-171
Open AccessA Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation
Great quantity of intergenic noncoding RNAs (lncRNAs) have been identified in the mammalian genome and involved in various biological processes, especially in the development and metastasis of cancer. In this study, we identified one lncRNA, lncRNA NONHSAT028712 (Lnc712), was highly expressed in breast cancer cell lines and tissues based on microarray screening. Knockdown of Lnc712 largely inhibited breast cancer cell proliferation. Mechanistically, Lnc712 bound specifically to heat-shock protein 90 (HSP90). Interaction between Lnc712 and HSP90 is required for HSP90 binding to cell division cycle 37 (Cdc37). The Lnc712/HSP90/Cdc37 complex regulated cyclin-dependent kinase 2 (CDK2) activation and then triggered breast cancer cell proliferation. In summary, our results identified a new lncRNA regulate breast cancer proliferation though interaction with HSP90.
- Open Access
- 3 June 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (6) , 431
Alternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma progression
Intersectin1 (ITSN1) contains two isoforms: ITSN1-S and ITSN1-L, which is highly regulated by alternative splicing. However, the alteration of alternative splicing and its importance in cancer is still unknown. In this study, our transcriptome analysis by using a large glioma cohort indicated the two isoforms exerted opposite function in glioma progression. Our previous results had shown ITSN1-S could promote glioma development; however, the function of ITSN1-L remained unknown. In this study, we first confirmed that ITSN1-L exerted an inhibitory role in glioma progression both in vivo and in vitro, which was contrary to the function of ITSN1-S. In additional, we also elucidated the mechanisms of ITSN1-L in inhibiting tumor progression. First, we revealed ITSN1-L could interact with α-tubulin to promote HDAC6-dependent deacetylation of ac-tubulin leading to decreased cell motility. Second, ITSN1-L could attenuate cell–substrate adhesion through FAK/integrin β3 pathway. Third, ITSN1-L was able to strengthen cell–cell adhesion by upregulating N-cadherin expression and its re-localization to membrane by ANXA2 and TUBB3/TUBB4. In conclusion, we found for the first time that two isoforms produced by alternative splicing exerted opposite functions in glioma development. Therefore, upregulation of ITSN1-L expression as well as downregulation of ITSN1-S expression probably was a better strategy in glioma treatment. Our present study laid a foundation for the importance of alternative splicing in glioma progression and raised the possibility of controlling glioma development completely at an alternative splicing level to be a more effective strategy.
- 3 June 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (6) , 431
Open AccessAlternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma progression
Intersectin1 (ITSN1) contains two isoforms: ITSN1-S and ITSN1-L, which is highly regulated by alternative splicing. However, the alteration of alternative splicing and its importance in cancer is still unknown. In this study, our transcriptome analysis by using a large glioma cohort indicated the two isoforms exerted opposite function in glioma progression. Our previous results had shown ITSN1-S could promote glioma development; however, the function of ITSN1-L remained unknown. In this study, we first confirmed that ITSN1-L exerted an inhibitory role in glioma progression both in vivo and in vitro, which was contrary to the function of ITSN1-S. In additional, we also elucidated the mechanisms of ITSN1-L in inhibiting tumor progression. First, we revealed ITSN1-L could interact with α-tubulin to promote HDAC6-dependent deacetylation of ac-tubulin leading to decreased cell motility. Second, ITSN1-L could attenuate cell–substrate adhesion through FAK/integrin β3 pathway. Third, ITSN1-L was able to strengthen cell–cell adhesion by upregulating N-cadherin expression and its re-localization to membrane by ANXA2 and TUBB3/TUBB4. In conclusion, we found for the first time that two isoforms produced by alternative splicing exerted opposite functions in glioma development. Therefore, upregulation of ITSN1-L expression as well as downregulation of ITSN1-S expression probably was a better strategy in glioma treatment. Our present study laid a foundation for the importance of alternative splicing in glioma progression and raised the possibility of controlling glioma development completely at an alternative splicing level to be a more effective strategy.
- 1 May 2018
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 37 (5) , 481-490
Long Noncoding RNA AK021443 Promotes Cell Proliferation and Migration by Regulating Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma Cells
Long noncoding RNAs (lncRNAs) were dysregulated in many kinds of cancers, including hepatocellular carcinoma (HCC). AK021443, as a novel lncRNA, was found to be upregulated in HCC, while its potential value and function are still unknown. The pathological changes of liver tissues were observed by hematoxylin and eosin staining. The expression levels of AK021443 in HCC tissues and cell lines were examined by quantitative real-time polymerase chain reaction (qRT-PCR). The proliferation ability of AK021443 on HepG2 and Bel-7402 cells was assessed by CCK8 and EdU staining assays. The role of AK021443 in HepG2 and Bel-7402 cell invasion and migration was measured by Transwell and wound healing assays. Finally, the expression of epithelial–mesenchymal transition (EMT) markers, including E-cadherin, N-cadherin, vimentin, and snail, was investigated by qRT-PCR, Western blot, and immunofluorescence. The role of AK021443in vivo was also analyzed. Hepatoma cell nucleus increased in HCC tissues compared with normal liver tissues. AK021443 expression was increased in HCC tissues and cell lines. Knockdown of AK021443 significantly reduced HepG2 and Bel-7402 cell proliferation, invasion, and migration. Furthermore, inhibition of AK021443 in HepG2 and Bel-7402 cells significantly repressed EMT ability. Knockdown of AK021443in vivo also significantly inhibited tumor growth with decreased Ki-67 levels and EMT phenotype in tumor tissues. However, these functions could be reversed by overexpression of AK021443. AK021443 significantly controlled HepG2 and Bel-7402 cell proliferation, colony formation, invasion, and migration by repressing EMT, which might provide a potential therapeutic target for HCC diagnosis.
- 1 May 2018
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 37 (5) , 481-490
Long Noncoding RNA AK021443 Promotes Cell Proliferation and Migration by Regulating Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma Cells
Long noncoding RNAs (lncRNAs) were dysregulated in many kinds of cancers, including hepatocellular carcinoma (HCC). AK021443, as a novel lncRNA, was found to be upregulated in HCC, while its potential value and function are still unknown. The pathological changes of liver tissues were observed by hematoxylin and eosin staining. The expression levels of AK021443 in HCC tissues and cell lines were examined by quantitative real-time polymerase chain reaction (qRT-PCR). The proliferation ability of AK021443 on HepG2 and Bel-7402 cells was assessed by CCK8 and EdU staining assays. The role of AK021443 in HepG2 and Bel-7402 cell invasion and migration was measured by Transwell and wound healing assays. Finally, the expression of epithelial–mesenchymal transition (EMT) markers, including E-cadherin, N-cadherin, vimentin, and snail, was investigated by qRT-PCR, Western blot, and immunofluorescence. The role of AK021443in vivo was also analyzed. Hepatoma cell nucleus increased in HCC tissues compared with normal liver tissues. AK021443 expression was increased in HCC tissues and cell lines. Knockdown of AK021443 significantly reduced HepG2 and Bel-7402 cell proliferation, invasion, and migration. Furthermore, inhibition of AK021443 in HepG2 and Bel-7402 cells significantly repressed EMT ability. Knockdown of AK021443in vivo also significantly inhibited tumor growth with decreased Ki-67 levels and EMT phenotype in tumor tissues. However, these functions could be reversed by overexpression of AK021443. AK021443 significantly controlled HepG2 and Bel-7402 cell proliferation, colony formation, invasion, and migration by repressing EMT, which might provide a potential therapeutic target for HCC diagnosis.